E. Bernard, H. Tuechler, P. Greenberg, R. Hasserjian, J. A. Arango Ossa, Y. Nannya, Sean M. Devlin, M. Creignou, Philippe Pinel, L. Monnier, G. Gundem, J. Medina-Martinez, D. Domenico, M. Jädersten, U. Germing, Guillermo Sanz, A. A. van de Loosdrecht, O. Kosmider, M. Follo, F. Thol, L. Zamora, R. F. Pinheiro, A. Pellagatti, H. K. Elias, D. Haase, C. Ganster, L. Adès, M. Tobiasson, L. Palomo, M. D. Della Porta, A. Takaori-Kondo, Takayuki Ishikawa, Shigeru Chiba, S. Kasahara, Yasushi Miyazaki, A. Viale, K. Huberman, P. Fenaux, M. Belickova, M. Savona, V. Klimek, Fabio P S Santos, J. Boultwood, Ioannis Kotsianidis, V. Santini, Francesc Solé, U. Platzbecker, M. Heuser, P. Valent, Kazuma Ohyashiki, C. Finelli, M. Voso, L. Shih, M. Fontenay, J. Jansen, José Cervera, N. Gattermann, Benjamin L. Ebert, R. Bejar, L. Malcovati, Mario Cazzola, S. Ogawa, E. Hellström-Lindberg, E. Papaemmanuil
2022.6.12NEJM Evidence
tlooto Summary
TP53multihit, FLT3 mutations, and MLLPTD were identified as top genetic predictors of adverse outcomes and IPSS-M improves prognostic discrimination across all clinical end points versus prior versions.
Abstract
MDS Molecular International Prognostic Scoring SystemSamples from over 2500 patients with MDS were profiled for gene mutations and used to develop the International Prognostic Scoring System-Molecular (IPSS-M). TP53multihit, FLT3 mutations, and MLLPTD were identified as top genetic predictors of adverse outcomes. IPSS-M improves prognostic discrimination across all clinical end points versus prior versions.
Citation format
BERNARD, E., et al. Molecular international prognostic scoring system for myelodysplastic syndromes. NEJM Evidence, 2022, 1 7: EVIDoa2200008.